DrJE-Salem (@drjesalem) 's Twitter Profile
DrJE-Salem

@drjesalem

CardioVasc-pharmacologist ♥️, cardiovasc-oncology🦀, cardiovasc-hormonology♀️♂️, cardio-immunology, QT⚡️, CardioVasc drug safety💔

ID: 1027036999440588800

calendar_today08-08-2018 03:41:16

762 Tweet

797 Followers

185 Following

Jarushka Naidoo (@drjnaidoo) 's Twitter Profile Photo

#ASCO25 💡Highlight of the Developmental Therapeutics/IO track today Catch our special session on severe IO toxicity: a real life irAE tumour board! Featuring… - Chair Sandrine Aspeslagh🇧🇪 - Med Onc #DougJohnson🇺🇸 - Cardio-Onc DrJE-Salem🇫🇷 - Neuro-Onc #JonProbasco🇺🇸 ASCO

#ASCO25 
💡Highlight of the Developmental Therapeutics/IO track today

Catch our special session on severe IO toxicity: a real life irAE tumour board! 

Featuring…
- Chair <a href="/sandrineaspesla/">Sandrine Aspeslagh</a>🇧🇪 
- Med Onc #DougJohnson🇺🇸 
- Cardio-Onc <a href="/DrJESalem/">DrJE-Salem</a>🇫🇷
- Neuro-Onc #JonProbasco🇺🇸 

<a href="/ASCO/">ASCO</a>
Sagal Pannu (@sagalpannu) 's Twitter Profile Photo

Started Day 3 of #ASCO25 with a fantastic session on rare and severe immunotherapy-related toxicities: insightful discussions on challenges and emerging management strategies!

Started Day 3 of #ASCO25 with a fantastic session on rare and severe immunotherapy-related toxicities: insightful discussions on challenges and emerging management strategies!
Javid Moslehi (@cardiooncology) 's Twitter Profile Photo

Excited to report this important collaboration which we hope helps us understand ICI-myocarditis better, published in #EHJ today! Along with the great DrJE-Salem! EHJ Editor-in-Chief Johann Bauersachs #CardioOnc UCSF Cardiology UCSF Helen Diller Family Comprehensive Cancer Ctr academic.oup.com/eurheartj/adva…

Excited to report this important collaboration which we hope helps us understand ICI-myocarditis better, published in #EHJ today! Along with the great <a href="/DrJESalem/">DrJE-Salem</a>!  <a href="/ehj_ed/">EHJ Editor-in-Chief</a> <a href="/JBauersachsMD/">Johann Bauersachs</a> #CardioOnc <a href="/UCSFCardiology/">UCSF Cardiology</a> <a href="/UCSFCancer/">UCSF Helen Diller Family Comprehensive Cancer Ctr</a> 

academic.oup.com/eurheartj/adva…
Javid Moslehi (@cardiooncology) 's Twitter Profile Photo

Here are the key risk factors: Presence of thymoma, Time of initial exposure to therapy, muscular symptoms, ECG criteria, LV dysfunction & degree of troponin elevation! Confirmed in a validation cohort through Mass General Brigham (special thanks to Osnat.Itzhaki & Anju Nohria!)

Here are the key risk factors: Presence of thymoma, Time of initial exposure to therapy, muscular symptoms, ECG criteria, LV dysfunction &amp; degree of troponin elevation! Confirmed in a validation cohort through <a href="/MassGenBrigham/">Mass General Brigham</a> (special thanks to <a href="/ItzhakiOsnat/">Osnat.Itzhaki</a> &amp; Anju Nohria!)
Javid Moslehi (@cardiooncology) 's Twitter Profile Photo

Lots of new data to go through but here is one critical 1: we still have a long way to go in terms of treatment for patients. Despite some early (& flawed) data, corticosteroids do nothing (even at high doses) for patients...

Lots of new data to go through but here is one critical 1: we still have a long way to go in terms of treatment for patients. Despite some early (&amp; flawed) data, corticosteroids do nothing (even at high doses) for patients...
John Power (@johnpowermd) 's Twitter Profile Photo

At last—our analysis predicting severe outcomes in ICI-myocarditis is out. With just ECG, LVEF, troponin, and clinical history, you can estimate risk at initial presentation. Grateful for the incredible mentorship Javid Moslehi DrJE-Salem .. true world-class investigators!

Pedro Moliner (@petermoliner) 's Twitter Profile Photo

This score will help distinguish severe from mild ICI-myocarditis. Many clinical implications‼️ In my opinion, this is one of the most clinically relevant papers on this topic to date. DrJE-Salem European Society of Cardiology Journals academic.oup.com/eurheartj/adva…

This score will help distinguish severe from mild ICI-myocarditis. Many clinical implications‼️

In my opinion, this is one of the most clinically relevant papers on this topic to date.

<a href="/DrJESalem/">DrJE-Salem</a> <a href="/ESC_Journals/">European Society of Cardiology Journals</a> 

academic.oup.com/eurheartj/adva…
drtarsh (@drtarsh) 's Twitter Profile Photo

The exceptionally eloquent ⁦DrJE-Salem⁩ outlining arrhythmia management in ICI myocarditis #ESCardioOnco2025 #oncology #cardiology

The exceptionally eloquent ⁦<a href="/DrJESalem/">DrJE-Salem</a>⁩ outlining arrhythmia management in ICI myocarditis #ESCardioOnco2025 #oncology #cardiology
Ruta Jasaityte (@jasaityteruta) 's Twitter Profile Photo

Very informative presentation by DrJE-Salem ⚠️ don't hurry up with antiarrhythmic therapy in ICI induced severe arrythmias and be aware of increased risk for developing of high grade conduction disorders #ESCardioOnc2025 #cardiooncology

Very informative presentation by <a href="/DrJESalem/">DrJE-Salem</a> ⚠️ don't hurry up with antiarrhythmic therapy in ICI induced severe arrythmias and  be aware of increased risk for developing of high grade conduction disorders #ESCardioOnc2025 #cardiooncology
Lorenz Lehmann (@lorenzlehmann) 's Twitter Profile Photo

Great science, packed rooms + so nice to meet all the collaborators and friends!!! Thanks for the perfect organization 🙏🏻#ESCardioOnco2025

Great science, packed rooms + so nice to meet all the collaborators and friends!!! Thanks for the perfect organization 🙏🏻#ESCardioOnco2025
EHJ Editor-in-Chief (@ehj_ed) 's Twitter Profile Photo

Assessing the Severity and Risks of ICI-Associated Myocarditis: Key Clinical Indicators in #EHJ! academic.oup.com/eurheartj/adva… #EHJ #cardiotwitter #myocarditis #oncology @ESC_journals European Society of Cardiology

Assessing the Severity and Risks of ICI-Associated Myocarditis: Key Clinical Indicators in  #EHJ!

academic.oup.com/eurheartj/adva…

#EHJ #cardiotwitter #myocarditis #oncology @ESC_journals <a href="/escardio/">European Society of Cardiology</a>
Circulation (@circaha) 's Twitter Profile Photo

Qin et al report the first use of ruxolitinib, a non-selective JAK inhibtor, in treatment of acute fulminant myocarditis. Using single-cell profiling, Ruxolitinib was shown to attenuate JAK/STAT signaling and modulate immune profiles. ahajournals.org/doi/full/10.11…

Qin et al report the first use of ruxolitinib, a non-selective JAK inhibtor, in treatment of acute fulminant myocarditis. Using single-cell profiling, Ruxolitinib was shown to attenuate JAK/STAT signaling and modulate immune profiles. ahajournals.org/doi/full/10.11…
Jarushka Naidoo (@drjnaidoo) 's Twitter Profile Photo

Risk score predicts poor outcomes in ICI-myocarditis John Power Javid Moslehi DrJE-Salem: -748pts with ICI-myo -thymoma, ⬆️trop (20, 200, >2000ULN), ⬇️QRS on ECG, LVEF<50%, CVS symps, assoc w poor outcome -risk score= 81% risk, 30-day poor outcome (validated, 🇺🇸+🇫🇷cohorts)

Risk score predicts poor outcomes in ICI-myocarditis <a href="/JohnPowerMD/">John Power</a> <a href="/CardioOncology/">Javid Moslehi</a> <a href="/DrJESalem/">DrJE-Salem</a>:

-748pts with ICI-myo
-thymoma, ⬆️trop (20, 200, &gt;2000ULN), ⬇️QRS on ECG, LVEF&lt;50%, CVS symps, assoc w poor outcome
-risk score= 81% risk, 30-day poor outcome (validated, 🇺🇸+🇫🇷cohorts)
Aarti Asnani (@aartiasnanimd) 's Twitter Profile Photo

New work by Chris Hoeger in our #CardioOnc program BIDMC CVI investigating cardiotoxicity of the commonly used Doxil/Avastin regimen rdcu.be/euyN6 Huge thanks to collaborators Sarju Ganatra, MD, FACC DrJE-Salem and BI team Nathalie Rosas, Reese Pinto, Rishi Wadhera, MD MPP, Meghan Shea